Drug
Golcadomide clinical trials
Also written BMS-986369 and CC-99282.
- studies test it
- 19
- open now
- 10
- in phase 3
- 2
- first study started
- 2020
Keep track of what changes. Save the golcadomide studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
19 studies that test it; most in 2024 (6)
| Year | Studies |
|---|---|
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 2 |
| 2023 | 1 |
| 2024 | 6 |
| 2025 | 5 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 12
- Phase 2
- 9
- Phase 3
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 10 · Other 9
Celgene (6) · Bristol-Myers Squibb (4) · The Lymphoma Academic Research Organisation (2) · Allison Winter (1) · Seoul National University Hospital (1) · Mayo Clinic (1) · M.D. Anderson Cancer Center (1) · Fondazione Italiana Linfomi - ETS (1)
Often tested with
Tested in the same studies.
Rituximab (4) · Obinutuzumab (2) · Iberdomide (1) · Vincristine (1) · Polatuzumab vedotin (1) · Pemetrexed (1) · Dexamethasone (1) · Poseltinib (1)
Studies
Open first, then newest update. How each study uses golcadomide is read from its arms, and is right about nine times in ten.
Testing it · 19
- Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell TherapyRecruitingPhase 2Mayo ClinicNCT06834373Written as Golcadomide
- A Study to Evaluate the Pharmacokinetics and Safety of Golcadomide in Participants With Severe Renal Impairment and End-Stage Renal Disease Compared With Participants With Normal Renal FunctionRecruitingPhase 1Bristol-Myers SquibbNCT07763418Written as Golcadomide
- Phase 2 Trial of Obinutuzumab and CC-99282 for Patients With Previously Untreated High Tumor Burden Follicular LymphomaRecruitingPhase 2M.D. Anderson Cancer CenterNCT06108232Written as CC-99282
- A Combination of Rituximab and CC-99282 as Front-line Therapy for Older Frail Patients With Diffuse Large B-cells Non-Hodgkin Lymphoma Evaluated With a Simplified Geriatric Assessment (sGA): a Phase II Study of the Fondazione Italiana Linfomi (FIL)RecruitingPhase 2Fondazione Italiana Linfomi - ETSNCT06835530Written as Rituximab + Golcadomide (CC-99282)
- Golcadomide With Pemetrexed, Rituximab, and Dexamethasone for Relapsed and Refractory CNS LymphomasNot yet recruitingPhase 1Allison WinterNCT07608731Written as Golcadomide
- Golcadomide Post-CAR T-cell in R/R Aggressive Large B-cell Lymphoma Patients With High Risk of RelapseRecruitingPhase 2The Lymphoma Academic Research OrganisationNCT06271057Written as golcadomide
- A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)RecruitingPhase 3CelgeneNCT06911502Written as Golcadomide
- CC-99282 + Rituximab Early Post CART for Non-Hodgkin's LymphomaRecruitingPhase 1Nathan DenlingerNCT06209619Written as Golcadomide
- A Platform Trial Evaluating New Drugs or Combination in R/R Peripheral T-cell LymphomasRecruitingPhase 1/2The Lymphoma Academic Research OrganisationNCT07018752Written as golcadomide
- Golcadomide, Poseltinib, and Rituximab for Relapsed/Refractory Diffuse Large B-cell LymphomaNot yet recruitingPhase 1/2Seoul National University HospitalNCT07269639Written as Golcadomide + Poseltinib + Rituximab
- A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3)Active, not recruitingPhase 1/2Bristol-Myers SquibbNCT06035497Written as BMS-986369
- A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular LymphomaActive, not recruitingPhase 2CelgeneNCT06425302Written as Golcadomide
- Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat LymphomaActive, not recruitingPhase 1CelgeneNCT04884035Written as CC-99282
- Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell LymphomaActive, not recruitingPhase 3CelgeneNCT06356129Written as Golcadomide
- Golcadomide and Nivolumab in Patients With Non-Hodgkin Lymphoma With Refractory Disease After Chimeric Antigen T-cell TherapyWithdrawnPhase 1/2University of PittsburghNCT06767956Written as GOLCADOMIDE
- Study to Assess Drug Levels and Safety of Golcadomide (BMS-986369) in Healthy Participants and Participants With Different Degrees of Hepatic ImpairmentCompletedPhase 1CelgeneNCT06535399Written as BMS-986369
- A Safety and Preliminary Efficacy Study of CC-99282 in Combination With Obinutuzumab in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaCompletedPhase 1CelgeneNCT04434196Written as CC-99282
- A Study to Evaluate the Drug Exposure of Single Ascending Doses of BMS-986369 and the Effect of Food on the BMS-986369 in Healthy ParticipantsCompletedPhase 1Bristol-Myers SquibbNCT05350800Written as BMS-986369
- A Study to Evaluate the Metabolism and Excretion of BMS-986369 in Healthy Male ParticipantsCompletedPhase 1Bristol-Myers SquibbNCT05567510Written as BMS-986369
Given in every arm · 8 — golcadomide is usual care beside what is tested
- A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin LymphomasRecruitingPhase 1/2Bristol-Myers SquibbNCT06090539Written as Golcadomide
- Golcadomide in Combination With Rituximab for the Treatment of Patients With Relapsed or Refractory Mantle Cell LymphomaRecruitingPhase 1/2City of Hope Medical CenterNCT07578077Written as Golcadomide
- Treatment Of Newly-diagnosed Follicular Lymphoma With CELMoD Golcadomide, Rituximab +/- Nivolumab.Active, not recruitingPhase 2Olivia Newton-John Cancer Research InstituteNCT05788081Written as golcadomide
- A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin LymphomaActive, not recruitingPhase 1Hoffmann-La RocheNCT05169515Written as Golcadomide
- A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin LymphomaActive, not recruitingPhase 2GenmabNCT05283720Written as CC-99282
- A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)Active, not recruitingPhase 1/2CelgeneNCT03930953Written as CC-99282
- A Study to Evaluate the Effect of Cytochrome P450 (CYP) 3A Inhibitor (Itraconazole) and Inducer (Rifampin) on the Drug Levels of Golcadomide (BMS-986369) in Healthy ParticipantsCompletedPhase 1CelgeneNCT06363630Written as Golcadomide
- A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell MalignanciesCompletedPhase 1/2CelgeneNCT03310619Written as CC-99282
Codes
What other systems call golcadomide · ClinicalTrials.gg INT014445
- UNII (FDA) 29HLR8Z5BRGOLCADOMIDEOne source FDA
- NCI Thesaurus C172396GolcadomideOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 29HLR8Z5BR | GOLCADOMIDE | One source FDA |
| NCI Thesaurus | C172396 | Golcadomide | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.